131 related articles for article (PubMed ID: 31421903)
1. OPCML: A Promising Biomarker and Therapeutic Avenue.
Simovic I; Castaño-Rodríguez N; Kaakoush NO
Trends Cancer; 2019 Aug; 5(8):463-466. PubMed ID: 31421903
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic deregulations of Wnt/β-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: Outcome of DNA methylation.
Singh V; Singh AP; Sharma I; Singh LC; Sharma J; Borthakar BB; Rai AK; Kataki AC; Kapur S; Saxena S
J Cancer Res Ther; 2019; 15(1):192-203. PubMed ID: 30880778
[TBL] [Abstract][Full Text] [Related]
3. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
4. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H
Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860
[TBL] [Abstract][Full Text] [Related]
5. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
7. Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.
Xing X; Cai W; Ma S; Wang Y; Shi H; Li M; Jiao J; Yang Y; Liu L; Zhang X; Chen M
BMC Cancer; 2017 Apr; 17(1):268. PubMed ID: 28407749
[TBL] [Abstract][Full Text] [Related]
8. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma].
Liu WJ; Wang L; Wang JP; Li JQ; Zhang CQ; Zheng L; Yuan YF
Ai Zheng; 2006 Jun; 25(6):696-700. PubMed ID: 16764763
[TBL] [Abstract][Full Text] [Related]
9. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
11. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
Mei FC; Young TW; Liu J; Cheng X
FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma.
Amornpisutt R; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Tumour Biol; 2015 Jul; 36(7):4973-8. PubMed ID: 25652468
[TBL] [Abstract][Full Text] [Related]
13. Elevated Expression of
Hu P; Huang Y; Gao Y; Yan H; Li X; Zhang J; Wang Y; Zhao Y
DNA Cell Biol; 2020 Apr; 39(4):522-532. PubMed ID: 32040344
[TBL] [Abstract][Full Text] [Related]
14. Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.
Birtley JR; Alomary M; Zanini E; Antony J; Maben Z; Weaver GC; Von Arx C; Mura M; Marinho AT; Lu H; Morecroft EVN; Karali E; Chayen NE; Tate EW; Jurewicz M; Stern LJ; Recchi C; Gabra H
Nat Commun; 2019 Jul; 10(1):3134. PubMed ID: 31316070
[TBL] [Abstract][Full Text] [Related]
15. OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma.
Ye F; Zhang SF; Xie X; Lu WG
Cancer Invest; 2008 Jul; 26(6):569-74. PubMed ID: 18584347
[TBL] [Abstract][Full Text] [Related]
16. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
[TBL] [Abstract][Full Text] [Related]
17. DERL3 functions as a tumor suppressor in gastric cancer.
Li Y; Liu H; Chen H; Shao J; Su F; Zhang S; Cai X; He X
Comput Biol Chem; 2020 Feb; 84():107172. PubMed ID: 31862624
[TBL] [Abstract][Full Text] [Related]
18. Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications.
Jahan R; Shah A; Kisling SG; Macha MA; Thayer S; Batra SK; Kaur S
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188362. PubMed ID: 32298747
[TBL] [Abstract][Full Text] [Related]
19. New roles opined for OPCML.
Wu SY; Sood AK
Cancer Discov; 2012 Feb; 2(2):115-6. PubMed ID: 22585855
[TBL] [Abstract][Full Text] [Related]
20. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Antony J; Zanini E; Birtley JR; Gabra H; Recchi C
Cancer Gene Ther; 2021 Feb; 28(1-2):18-26. PubMed ID: 32595215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
